Retatrutide Weight Loss: What the Trial Data Actually Shows

The first generation of GLP-1 drugs, like semaglutide, work by mimicking a single gut hormone that tells your brain you're full. Tirzepatide (Mounjaro, Zepbound) added a second receptor, GIP, which improved both weight loss and blood sugar control. Retatrutide takes the next step. It activates three receptors: GLP-1, GIP, and glucagon. The glucagon component is what makes it different from everything else on the market. While GLP-1 and GIP reduce appetite and improve insulin sensitivity, glucagon activation increases energy expenditure. Your body burns more calories at rest. Eli Lilly has been developing retatrutide since the early 2020s. Phase 2 results were already impressive. Phase 3 data, released in late 2025 and early 2026, confirmed that the triple mechanism produces weight loss beyond what any single or dual agonist has achieved.

Retatrutide is a weekly subcutaneous injection, similar to semaglutide and tirzepatide. It binds to three receptors:

• GLP-1 receptor. Reduces appetite, slows gastric emptying, improves insulin secretion.
• GIP receptor. Enhances insulin sensitivity and may improve fat metabolism.
• Glucagon receptor. Increases energy expenditure and promotes fat oxidation.

The combination means you eat less (GLP-1 and GIP effects) and burn more (glucagon effect). This dual action on both sides of the energy equation is why the weight loss numbers are so much higher than single-mechanism drugs.

The most important data comes from the TRIUMPH 4 Phase 3 trial:

• 28.7% average weight loss at 68 weeks with the 12 mg dose
• That translates to about 71 pounds lost for a 250-pound person
• Weight loss was dose-dependent, with lower doses producing less
• Additional improvements in knee pain (75.8% reduction) and physical function
• Participants had obesity and knee osteoarthritis

Earlier Phase 2 data showed:

• At 12 mg, participants averaged 9.8% weight loss by week 12 alone
• HbA1c reductions of about 2 percentage points in people with type 2 diabetes
• Improvements in blood pressure, liver fat, and lipid levels

Side effects are consistent with the incretin drug class. Nausea, diarrhea, and other GI symptoms are common during dose escalation and generally mild. No new safety signals emerged in Phase 3.

People in clinical trials describe the appetite suppression as strong, sometimes stronger than what they experienced on semaglutide or tirzepatide. One user on r/Peptides who participated in a related trial noted that “the first four weeks were rough with nausea, but after that it was like the food noise just disappeared completely.“ Another poster described the weight loss trajectory: “The first month was maybe 8 pounds. Then it slowed to about 2-3 pounds a week and stayed there. Steady, not dramatic, but it never stopped.“

• Significant weight loss, beyond what semaglutide or tirzepatide typically produce
• Reduced appetite and food cravings
• Improved blood sugar control
• Lower blood pressure
• Reduced liver fat
• Improved joint pain and mobility (especially in people with knee osteoarthritis)
• Increased energy expenditure at rest

This is the comparison most people want. Here's what the data shows: | Metric | Retatrutide (12 mg) | Tirzepatide (15 mg) | |--------|---------------------|---------------------| | Average weight loss | ~28.7% | ~22.5% | | Mechanism | Triple agonist (GLP-1/GIP/glucagon) | Dual agonist (GLP-1/GIP) | | FDA status | Not yet approved | Approved | | Dosing | Weekly injection | Weekly injection | | GI side effects | Similar | Similar | Retatrutide produces more weight loss, but it isn't available yet. Tirzepatide is on the market now. If you're starting treatment today, tirzepatide is the most effective option currently available.

Retatrutide is a standalone pharmaceutical, not a peptide you'd stack in the traditional sense. But people using it for weight loss sometimes combine it with:

• BPC-157 for gut health support, since GLP-1 drugs can cause GI discomfort
• MOTs-C for additional metabolic support
• AOD-9604 for targeted fat metabolism

These combinations are not studied in clinical trials. They're based on user reports and practitioner experience.